Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK S AMSTER

Allopathic & Osteopathic Physicians Dermatology

NPI
1518947068
CMS profile
434915
Location
BRIGHTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,741.81

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,054.74 72
Travel and Lodging $502.09 3
Education $184.98 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK S AMSTER

NPI 1518947068 · CMS profile ID 434915

Allopathic & Osteopathic Physicians / Dermatology

BRIGHTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518947068?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK S AMSTER, NPI 1518947068, CMS profile ID 434915. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518947068?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MARK S AMSTER, NPI 1518947068, CMS profile ID 434915. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518947068?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MARK S AMSTER, NPI 1518947068, CMS profile ID 434915, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518947068?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $2,741.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $30.9206/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988267121 CMS
Incyte Corporation $9.2206/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044400171 CMS
PFIZER INC. $19.5106/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050647277 CMS
Incyte Corporation $58.8305/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044400179 CMS
PFIZER INC. $20.8505/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050493945 CMS
Janssen Biotech, Inc. $36.9105/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988267129 CMS
AbbVie Inc. $28.5005/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996143013 CMS
Incyte Corporation $8.3205/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044400099 CMS
LEO Pharma Inc. $18.6104/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053449961 CMS
Janssen Biotech, Inc. $18.9404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988267111 CMS
E.R. Squibb & Sons, L.L.C. $9.9404/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014983011 CMS
Janssen Biotech, Inc. $18.9804/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988267137 CMS
PFIZER INC. $26.9604/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049101745 CMS
Lilly USA, LLC $17.1004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031819173 CMS
Janssen Biotech, Inc. $84.9903/28/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988267101 CMS
AbbVie Inc. $15.0503/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996143011 CMS
PFIZER INC. $6.7203/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050583815 CMS
AbbVie Inc. $16.8203/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996143009 CMS
Sun Pharmaceutical Industries Inc. $25.5102/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053917567 CMS
E.R. Squibb & Sons, L.L.C. $7.4802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014982895 CMS
Incyte Corporation $13.6202/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044400043 CMS
Lilly USA, LLC $15.0102/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031838525 CMS
AbbVie Inc. $32.0602/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996143007 CMS
E.R. Squibb & Sons, L.L.C. $20.8101/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014982887 CMS
E.R. Squibb & Sons, L.L.C. $6.4901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014982879 CMS
PFIZER INC. $25.4101/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050341131 CMS
Incyte Corporation $27.1101/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044399987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $948.24 41
PY2020 $1,698.64 40
PY2021 $2,885.74 49
PY2022 $908.76 39
PY2023 $2,741.81 77
PY2024 $10,226.70 116
PY2025 $7,944.65 121

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $53,844.93 1
PY2025 Principal investigator $766,490.54 300
PY2024 Recipient $128,058.59 21
PY2024 Principal investigator $897,472.63 409
PY2023 Recipient $1,968.87 12
PY2023 Principal investigator $564,775.48 186
PY2022 Principal investigator $476,701.63 55
PY2021 Recipient $83.79 1
PY2021 Principal investigator $1,009,862.81 112
PY2020 Principal investigator $796,272.63 112
PY2019 Recipient $900.00 1
PY2019 Principal investigator $445,749.07 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

301 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202532320
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 12/31/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870329
Principal investigator 1 Janssen Research & Development, LLC $1.00 12/25/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378417
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 12/25/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378499
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 12/24/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433983
Principal investigator 1 ABBVIE INC. $2,500.00 12/23/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202531724
Principal investigator 1 SANOFI US SERVICES INC. $100.00 12/22/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114887
Principal investigator 1 SANOFI US SERVICES INC. $7,736.00 12/22/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114893
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500417
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500420
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500425
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500429
Principal investigator 1 Incyte Corporation $1,634.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500458
Principal investigator 1 Incyte Corporation $1,634.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500461
Principal investigator 1 Incyte Corporation $2,281.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500477
Principal investigator 1 Incyte Corporation $2,362.00 12/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500481
Principal investigator 1 Incyte Corporation $1,989.00 12/19/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557191
Principal investigator 1 Tanabe Pharma America, Inc. $270.26 12/19/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870923
Principal investigator 1 SANOFI PASTEUR INC. $650.00 12/18/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226089322
Principal investigator 1 Janssen Research & Development, LLC $3,771.00 12/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378408
Principal investigator 1 Tanabe Pharma America, Inc. $825.00 12/11/2025 Non-covered Recipient Entity
CLINICAL TRIAL SOURCE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870913
Principal investigator 1 Incyte Corporation $501.60 12/08/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500440
Principal investigator 1 Incyte Corporation $3,569.50 12/05/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500432
Principal investigator 1 SANOFI PASTEUR INC. $109.72 12/05/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226089316
Principal investigator 1 Incyte Corporation $693.00 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557155
Principal investigator 1 Incyte Corporation $124.90 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557161
Principal investigator 1 Incyte Corporation $17,779.30 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557167
Principal investigator 1 Incyte Corporation $3,847.50 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557171
Principal investigator 1 Incyte Corporation $6,857.10 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557174
Principal investigator 1 Incyte Corporation $2,900.70 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557180
Principal investigator 1 Incyte Corporation $12,099.90 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557197
Principal investigator 1 Incyte Corporation $346.50 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557203
Principal investigator 1 Incyte Corporation $1,851.30 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557212
Principal investigator 1 Incyte Corporation $350.00 12/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557217
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,539.45 12/04/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433979
Principal investigator 1 Tanabe Pharma America, Inc. $1,600.39 12/04/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870925
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557222
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557227
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557233
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557239
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557247
Principal investigator 1 Incyte Corporation $34.35 12/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557256
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 12/01/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378548
Principal investigator 1 ABBVIE INC. $4,051.00 11/28/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202526108
Principal investigator 1 Janssen Research & Development, LLC $792.00 11/27/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378396
Principal investigator 1 Incyte Corporation $47.00 11/21/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500464
Principal investigator 1 Incyte Corporation $47.00 11/21/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500469
Principal investigator 1 Incyte Corporation $2,362.00 11/21/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500473
Principal investigator 1 Incyte Corporation $1,069.30 11/21/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500490
Principal investigator 1 Incyte Corporation $2,550.00 11/19/2025 Non-covered Recipient Entity
METROBOSTON CLINICAL PARTNERS LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1240557320
Principal investigator 1 ABBVIE INC. $7,613.76 11/18/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202524565
Principal investigator 1 SANOFI US SERVICES INC. $3,136.00 11/10/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114875
Principal investigator 1 ABBVIE INC. $3,251.55 11/05/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521837
Principal investigator 1 ABBVIE INC. $153.00 11/05/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521913
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 11/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870337
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,641.29 10/30/2025 Non-covered Recipient Entity
Metro Boston Clinical Partners
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235995763
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,238.44 10/28/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307167
Principal investigator 1 Janssen Research & Development, LLC $1,920.00 10/27/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378455
Principal investigator 1 Janssen Research & Development, LLC $3,183.00 10/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378491
Principal investigator 1 Incyte Corporation $1,129.10 10/22/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500449
Principal investigator 1 Incyte Corporation $1,764.00 10/22/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500454
Principal investigator 1 Incyte Corporation $47.00 10/22/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500484
Principal investigator 1 Incyte Corporation $47.00 10/22/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500487
Principal investigator 1 Incyte Corporation $1,572.00 10/20/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500436
Principal investigator 1 Incyte Corporation $1,145.10 10/20/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500445
Recipient Nielsen BioSciences, Inc. $53,844.93 10/15/2025 Covered Recipient Physician CFW-A No dispute reported 06/30/2026 1214953878
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,154.59 10/10/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433974
Principal investigator 1 ABBVIE INC. $1,341.60 10/09/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202513975
Principal investigator 1 ABBVIE INC. $1,626.45 10/09/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202515309
Principal investigator 1 Incyte Corporation $9,000.00 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557097
Principal investigator 1 Incyte Corporation $106.65 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557101
Principal investigator 1 Incyte Corporation $7,870.50 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557111
Principal investigator 1 Incyte Corporation $1,000.00 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557118
Principal investigator 1 Incyte Corporation $81.00 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557124
Principal investigator 1 Incyte Corporation $2,900.70 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557131
Principal investigator 1 Incyte Corporation $4,313.70 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557135
Principal investigator 1 Incyte Corporation $1,500.00 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557140
Principal investigator 1 Incyte Corporation $7,019.10 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557146
Principal investigator 1 Incyte Corporation $5,457.60 10/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557151
Principal investigator 1 Tanabe Pharma America, Inc. $1,307.70 10/03/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870945
Principal investigator 1 Janssen Research & Development, LLC $11,000.00 10/02/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378378
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,419.40 10/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190307169
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 10/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870339
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 09/29/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378446
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,950.00 09/26/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433966
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,384.86 09/26/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433970
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500298
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500302
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500307
Principal investigator 1 Incyte Corporation $1,764.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500310
Principal investigator 1 Incyte Corporation $1,806.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500312
Principal investigator 1 Incyte Corporation $1,904.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500321
Principal investigator 1 Incyte Corporation $1,806.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500324
Principal investigator 1 Incyte Corporation $1,764.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500329
Principal investigator 1 Incyte Corporation $1,715.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500333
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500337
Principal investigator 1 Incyte Corporation $1,548.10 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500341
Principal investigator 1 Incyte Corporation $1,904.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500345
Principal investigator 1 Incyte Corporation $1,806.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500349
Principal investigator 1 Incyte Corporation $1,715.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500353
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500356
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500381
Principal investigator 1 Incyte Corporation $81.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500385
Principal investigator 1 Incyte Corporation $1,904.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500389
Principal investigator 1 Incyte Corporation $2,679.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500394
Principal investigator 1 Incyte Corporation $2,679.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500397
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500401
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500405
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500409
Principal investigator 1 Incyte Corporation $47.00 09/25/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500414
Principal investigator 1 Janssen Research & Development, LLC $1,584.00 09/25/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378539
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 09/24/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166780
Principal investigator 1 SANOFI US SERVICES INC. $4,505.00 09/15/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114858
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 09/08/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378514
Principal investigator 1 ABBVIE INC. $51.00 09/05/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202510152
Principal investigator 1 Incyte Corporation $8,000.00 09/05/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500295
Principal investigator 1 Incyte Corporation $1,500.00 09/05/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240500317
Principal investigator 1 ABBVIE INC. $2,580.60 09/04/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202508944
Principal investigator 1 Janssen Research & Development, LLC $9,475.00 09/01/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378483
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 09/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870341
Principal investigator 1 Incyte Corporation $1,414.80 08/20/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500369
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,154.59 08/20/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433962
Principal investigator 1 SANOFI US SERVICES INC. $3,466.00 08/18/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114845
Principal investigator 1 Incyte Corporation $382.50 08/15/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500377
Principal investigator 1 Tanabe Pharma America, Inc. $25,427.53 08/14/2025 Non-covered Recipient Entity
CLINICAL TRIAL SOURCE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870909
Principal investigator 1 SANOFI US SERVICES INC. $14,250.00 08/11/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226114836
Principal investigator 1 ABBVIE INC. $1,341.60 08/06/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502749
Principal investigator 1 ABBVIE INC. $1,811.10 08/05/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501498
Principal investigator 1 Incyte Corporation $2,146.05 08/04/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500373
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 08/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870327
Principal investigator 1 Tanabe Pharma America, Inc. $5,520.00 07/31/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870929
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 07/31/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870931
Principal investigator 1 Incyte Corporation $5,500.00 07/28/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500360
Principal investigator 1 Incyte Corporation $750.00 07/28/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500364
Principal investigator 1 Incyte Corporation $693.00 07/22/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557051
Principal investigator 1 Tanabe Pharma America, Inc. $1,455.30 07/22/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870927
Principal investigator 1 Tanabe Pharma America, Inc. $2,193.03 07/22/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870933
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,384.86 07/18/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433958
Principal investigator 1 Incyte Corporation $346.50 07/17/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557038
Principal investigator 1 SANOFI US SERVICES INC. $7,406.00 07/14/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114799
Principal investigator 1 SANOFI US SERVICES INC. $475.00 07/14/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114803
Principal investigator 1 ABBVIE INC. $102.00 07/10/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202498010
Principal investigator 1 Incyte Corporation $7,979.40 07/10/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557045
Principal investigator 1 ABBVIE INC. $2,631.90 07/08/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497404
Principal investigator 1 ABBVIE INC. $882.60 07/02/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202496339
Principal investigator 1 ABBVIE INC. $3,046.65 07/02/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202496341
Principal investigator 1 Incyte Corporation $24.68 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557056
Principal investigator 1 Incyte Corporation $4.24 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557062
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557066
Principal investigator 1 Incyte Corporation $16.18 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557072
Principal investigator 1 Incyte Corporation $34.35 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557078
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557082
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557087
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557090
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 07/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870331
Principal investigator 1 Janssen Research & Development, LLC $792.00 06/30/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378431
Principal investigator 1 Janssen Research & Development, LLC $2,328.00 06/30/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378471
Principal investigator 1 SANOFI PASTEUR INC. $350.00 06/25/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226089297
Principal investigator 1 Incyte Corporation $4,761.90 06/24/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556901
Principal investigator 1 Incyte Corporation $3,742.20 06/19/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556907
Principal investigator 1 Incyte Corporation $350.00 06/19/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556919
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,154.59 06/18/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433954
Principal investigator 1 SANOFI US SERVICES INC. $4,307.00 06/16/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114787
Principal investigator 1 Incyte Corporation $3,455.10 06/12/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556913
Principal investigator 1 Incyte Corporation $1,456.35 06/06/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500292
Principal investigator 1 Eli Lilly and Company $5,300.00 06/05/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889096
Principal investigator 1 ABBVIE INC. $1,398.60 06/03/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202488521
Principal investigator 1 ABBVIE INC. $2,631.90 06/03/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488523
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 06/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870333
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,384.86 05/29/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433949
Principal investigator 1 Incyte Corporation $3,354.30 05/28/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556875
Principal investigator 1 Incyte Corporation $350.00 05/28/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556892
Principal investigator 1 Tanabe Pharma America, Inc. $1,331.24 05/28/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870941
Principal investigator 1 Tanabe Pharma America, Inc. $275.00 05/28/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870943
Principal investigator 1 Janssen Research & Development, LLC $6,116.00 05/26/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378385
Principal investigator 1 Incyte Corporation $693.00 05/22/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556897
Principal investigator 1 Janssen Research & Development, LLC $792.00 05/22/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378507
Principal investigator 1 SANOFI US SERVICES INC. $10,068.00 05/19/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114793
Principal investigator 1 ABBVIE INC. $102.00 05/15/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484935
Principal investigator 1 Incyte Corporation $2,316.60 05/15/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556884
Principal investigator 1 Tanabe Pharma America, Inc. $1,307.70 05/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870937
Principal investigator 1 Tanabe Pharma America, Inc. $1,331.24 05/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870939
Principal investigator 1 Incyte Corporation $346.50 05/08/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556868
Principal investigator 1 Tanabe Pharma America, Inc. $1,026.00 05/08/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870935
Principal investigator 1 ABBVIE INC. $51.00 05/07/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482393
Principal investigator 1 ABBVIE INC. $3,162.75 05/07/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482395
Principal investigator 1 ABBVIE INC. $1,473.90 05/07/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482397
Principal investigator 1 Incyte Corporation $1,456.35 05/07/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500288
Principal investigator 1 Janssen Research & Development, LLC $792.00 05/05/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378477
Principal investigator 1 Incyte Corporation $0.31 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556969
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556976
Principal investigator 1 Incyte Corporation $4.86 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556982
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556988
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556996
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557006
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557012
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557020
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 05/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870335
Principal investigator 1 Incyte Corporation $2,045.70 04/28/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556864
Principal investigator 1 Janssen Research & Development, LLC $2,920.00 04/28/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378438
Principal investigator 1 Amgen Inc. $43,532.00 04/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246646543
Principal investigator 1 Tanabe Pharma America, Inc. $1,401.30 04/23/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870921
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,475.21 04/17/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433945
Principal investigator 1 Incyte Corporation $7,407.90 04/15/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556859
Principal investigator 1 Tanabe Pharma America, Inc. $1,307.70 04/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870917
Principal investigator 1 Tanabe Pharma America, Inc. $1,026.00 04/15/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870919
Principal investigator 1 SANOFI US SERVICES INC. $12,838.00 04/14/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114780
Principal investigator 1 Incyte Corporation $2,494.80 04/08/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556853
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 04/07/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433940
Principal investigator 1 ABBVIE INC. $1,653.45 04/03/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471125
Principal investigator 1 ABBVIE INC. $2,580.60 04/03/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202471130
Principal investigator 1 ABBVIE INC. $51.00 04/03/2025 Non-covered Recipient Entity
METRO BOSTON
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202471515
Principal investigator 1 Incyte Corporation $137.80 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556926
Principal investigator 1 Incyte Corporation $180.20 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556932
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556938
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556944
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556949
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556955
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556959
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556965
Principal investigator 1 Incyte Corporation $5.30 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557002
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557026
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557034
Principal investigator 1 SANOFI US SERVICES INC. $5,211.50 04/02/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226114762
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/02/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226114774
Principal investigator 1 Incyte Corporation $27,144.90 04/01/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556848
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 04/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870325
Principal investigator 1 Tanabe Pharma America, Inc. $1,455.30 04/01/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870915
Principal investigator 1 Janssen Research & Development, LLC $5,112.00 03/27/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166763
Principal investigator 1 Amgen Inc. $2,500.00 03/25/2025 Non-covered Recipient Entity
METROBOSTON CLINICAL PARTNERS
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246644587
Principal investigator 1 Janssen Research & Development, LLC $3,521.00 03/24/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378401
Principal investigator 1 SANOFI US SERVICES INC. $3,245.00 03/24/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114751
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 03/24/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226114768
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,090.35 03/24/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433937
Principal investigator 1 SANOFI PASTEUR INC. $1,885.10 03/21/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226089255
Principal investigator 1 Janssen Research & Development, LLC $792.00 03/20/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166771
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 03/17/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175166681
Principal investigator 1 Incyte Corporation $8,000.00 03/14/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557308
Principal investigator 1 Incyte Corporation $1,500.00 03/14/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557315
Principal investigator 1 Incyte Corporation $1,456.35 03/12/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500284
Principal investigator 1 Tanabe Pharma America, Inc. $1,455.30 03/11/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870951
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/10/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166688
Principal investigator 1 Janssen Research & Development, LLC $8,500.00 03/10/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166788
Principal investigator 1 ABBVIE INC. $1,473.90 03/07/2025 Non-covered Recipient Entity
METRO BOSTON
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461865
Principal investigator 1 Incyte Corporation $350.00 03/04/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240556784
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556790
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556795
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556801
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556806
Principal investigator 1 Incyte Corporation $9.72 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556812
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556818
Principal investigator 1 Incyte Corporation $118.26 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556823
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556829
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556835
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240556840
Principal investigator 1 Janssen Research & Development, LLC $9,403.00 03/03/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378424
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,410.98 03/03/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433933
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 03/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870347
Principal investigator 1 Tanabe Pharma America, Inc. $2,615.40 02/25/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870959
Principal investigator 1 Tanabe Pharma America, Inc. $2,052.00 02/25/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870961
Principal investigator 1 SANOFI US SERVICES INC. $8,783.50 02/24/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226114731
Principal investigator 1 Incyte Corporation $1,456.35 02/19/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500274
Principal investigator 1 Janssen Research & Development, LLC $448.00 02/18/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166726
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 02/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870953
Principal investigator 1 Tanabe Pharma America, Inc. $2,500.00 02/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870955
Principal investigator 1 Tanabe Pharma America, Inc. $500.00 02/18/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870963
Principal investigator 1 Janssen Research & Development, LLC $792.00 02/17/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378521
Principal investigator 1 SANOFI US SERVICES INC. $2,913.00 02/10/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114726
Principal investigator 1 Incyte Corporation $96.00 02/07/2025 Non-covered Recipient Entity
AFFILIATED DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500280
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,154.59 02/07/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433929
Principal investigator 1 ABBVIE INC. $2,815.50 02/06/2025 Non-covered Recipient Entity
METRO BOSTON
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447787
Principal investigator 1 ABBVIE INC. $1,653.45 02/06/2025 Non-covered Recipient Entity
METRO BOSTON
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447791
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/06/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166744
Principal investigator 1 Janssen Research & Development, LLC $700.00 02/05/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166718
Principal investigator 1 ABBVIE INC. $102.00 02/04/2025 Non-covered Recipient Entity
METRO BOSTON
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202443743
Principal investigator 1 SANOFI PASTEUR INC. $11,120.32 02/03/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226089267
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 02/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870345
Principal investigator 1 Incyte Corporation $2,600.10 01/29/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557300
Principal investigator 1 Janssen Research & Development, LLC $6,468.00 01/27/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378463
Principal investigator 1 Janssen Research & Development, LLC $792.00 01/27/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175378528
Principal investigator 1 Incyte Corporation $11,223.00 01/21/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557268
Principal investigator 1 SANOFI US SERVICES INC. $4,284.00 01/21/2025 Non-covered Recipient Entity
Physicians Research Group Ii Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226114740
Principal investigator 1 Tanabe Pharma America, Inc. $4,311.90 01/21/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870957
Principal investigator 1 Incyte Corporation $2,554.20 01/17/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557262
Principal investigator 1 Incyte Corporation $350.00 01/17/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557296
Principal investigator 1 Janssen Research & Development, LLC $142.00 01/17/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175166697
Principal investigator 1 Janssen Research & Development, LLC $156.00 01/17/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175166703
Principal investigator 1 Janssen Research & Development, LLC $574.00 01/17/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175166735
Principal investigator 1 Janssen Research & Development, LLC $156.00 01/17/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175166752
Principal investigator 1 Janssen Research & Development, LLC $3,845.00 01/16/2025 Non-covered Recipient Entity
Physicians Rsrch Group
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175166712
Principal investigator 1 PFIZER INC. $3,750.00 01/15/2025 Non-covered Recipient Entity
Physicians Research Group II LLC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228801871
Principal investigator 1 Tanabe Pharma America, Inc. $71.15 01/14/2025 Non-covered Recipient Entity
CLINICAL TRIAL SOURCE LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870911
Principal investigator 1 ABBVIE INC. $102.00 01/09/2025 Non-covered Recipient Entity
METRO BOSTON
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202437563
Principal investigator 1 Amgen Inc. $29,219.09 01/08/2025 Non-covered Recipient Entity
METROBOSTON CLINICAL PARTNERS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246644583
Principal investigator 1 Incyte Corporation $350.00 01/07/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557277
Principal investigator 1 Incyte Corporation $5,682.60 01/07/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557285
Principal investigator 1 Incyte Corporation $500.00 01/07/2025 Non-covered Recipient Entity
METRO BOSTON CLINICAL PARTNERS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557290
Principal investigator 1 Tanabe Pharma America, Inc. $2,802.60 01/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria No dispute reported 06/30/2026 1243870947
Principal investigator 1 Tanabe Pharma America, Inc. $275.00 01/07/2025 Non-covered Recipient Entity
PHYSICIANS RESEARCH GROUP II LLC
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870949
Principal investigator 1 ABBVIE INC. $1,618.35 01/02/2025 Non-covered Recipient Entity
METRO BOSTON
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202434308
Principal investigator 1 Tanabe Pharma America, Inc. $70.00 01/01/2025 Non-covered Recipient Entity
MetroBoston Clinical Partners
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) No dispute reported 06/30/2026 1243870343